Open access · CC-BY
via OpenAlex
Targeting cellular senescence with novel senotherapeutics by design to extend healthspan
Lei Justan Zhang, Brian M. Hughes, Luise A. Angelini, Ryan D. O'Kelly, Matthew J. Yousefzadeh, Ted Kamenecka, Laura J. Niedernhofer, Paul D. Robbins
Innovation in Aging · 2021
Abstract
Abstract Senescent cells accumulate with age in various tissues and organs, leading to the decline in tissue function and deterioration of many age-related diseases and aging. Senolytics(definition) have emerged as an effective therapeutic approach to eliminate senescent cells to improve aging phenotypes and associated co-morbidities. Despite their promising potential, only a handful of senolytics have been reported, including a natural flavonoid fisetin discovered by our group. Fisetin has been shown to reduce senescence(definition), suppress age-related pathology, and extend healthspan(definition) in aged mice. However, its moderate potency, potential mutagenic risk and poor bioavailability have limited its further clinical applications. By leveraging drug design, medicinal chemistry and high-content imaging analysis, we have successfully optimized the senolytic activity of fisetin, leading to the identification of two improved fisetin senolytic analogs (FAs) with reduced toxicity in non-senescent cells. The improved senolytic activity of these FAs was demonstrated in murine and human senescent cell models as well as in accelerated aging and naturally aged mouse models. The analysis of the senolytic activity of the FAs as well as several other recently identified senolytics, including a senolytic lipid, will be presented.
◌ CITATION ONLY
Full text is not openly licensed for redistribution here. Read it at the source:
Provenance
- Source
- OpenAlex
- DOI
- 10.1093/geroni/igab046.2564
- Canonical
- link ↗
- Fetched
- 2026-10-11 MST
Cite this
APA
Zhang, L.J., Hughes, B.M., Angelini, L.A., O'Kelly, R.D., Yousefzadeh, M.J., Kamenecka, T., Niedernhofer, L.J., & Robbins, P.D. (2021). Targeting cellular senescence with novel senotherapeutics by design to extend healthspan. <em>Innovation in Aging</em>. https://doi.org/10.1093/geroni/igab046.2564
Vancouver
Zhang LJ, Hughes BM, Angelini LA, O'Kelly RD, Yousefzadeh MJ, Kamenecka T, et al. Targeting cellular senescence with novel senotherapeutics by design to extend healthspan. Innovation in Aging. 2021. doi:10.1093/geroni/igab046.2564.
BibTeX
@article{lei2021Target,
title = {Targeting cellular senescence with novel senotherapeutics by design to extend healthspan},
author = {Lei Justan Zhang and Brian M. Hughes and Luise A. Angelini and Ryan D. O'Kelly and Matthew J. Yousefzadeh and Ted Kamenecka and Laura J. Niedernhofer and Paul D. Robbins},
journal = {Innovation in Aging},
year = {2021},
doi = {10.1093/geroni/igab046.2564},
}
Research neighborhood
References, citing works, and semantically nearest findings. Click a node to open it.
Related findings
Aging Cell 2026
Open access · CC-BY
Novel Flavonoid Senotherapeutics Identified by Phenotypic Drug Discovery Reduce Senescence and Improve Multiple Markers of Healthspan
Aging cell 2026
Citation only
Novel Flavonoid Senotherapeutics Identified by Phenotypic Drug Discovery Reduce Senescence and Improve Multiple Markers of Healthspan.
bioRxiv (Cold Spring Harbor Laboratory) 2022
Preprint · OA
Fisetin Attenuates Cellular Senescence Accumulation During Culture Expansion of Human Adipose-Derived Stem Cells
European Heart Journal 2024
Open access · OA
Can removal of zombie cells revitalize the aging cardiovascular system?
International Journal of Pharmacology and Clinical Research (IJPCR) 2026
Open access · CC-BY
Comprehensive Review of Senotherapy
CU Scholar (University of Colorado Boulder) 2025
Preprint